TEVA Stock Performance, Insider Transaction and News

TEVA - Teva Pharmaceutical Industries

Market Cap	10.66B	P/E	-	EPS this Y	-4.70%	Ern Qtrly Grth	-
Income	-453M	Forward P/E	3.78	EPS next Y	13.50%	50D Avg Chg	19.00%
Sales	16.29B	PEG	4.52	EPS past 5Y	-0.30%	200D Avg Chg	4.00%
Dividend	N/A	Price/Book	1.32	EPS next 5Y	1.60%	52W High Chg	-19.00%
Recommedations	2.10	Quick Ratio	0.46	Shares Outstanding	1.13B	52W Low Chg	30.00%
Insider Own	0.00%	ROA	5.16%	Shares Float	1.13B	Beta	0.88
Inst Own	54.85%	ROE	-10.51%	Shares Shorted/Prior	30.34M/23.99M	Price	9.25
Gross Margin	49.50%	Profit Margin	-2.78%	Avg. Volume	14,211,503	Target Price	21.14
Oper. Margin	19.62%	Earnings Date	Nov 6	Volume	32,973,594	Change	11.58%

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva Pharmaceutical Industries News

02:47 AM	Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
11/15/24	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
11/08/24	Teva to Present at the Jefferies London Healthcare Conference
11/08/24	Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
11/07/24	Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
11/07/24	TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
11/07/24	Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...
11/06/24	'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe.
11/06/24	Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
11/06/24	Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
11/06/24	Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
11/06/24	Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
11/05/24	What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
11/04/24	Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
11/01/24	Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
11/01/24	Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
11/01/24	Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
11/01/24	EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
10/31/24	Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
10/31/24	EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug

TEVA Chatroom

NNJAWINLIVE Posted - 5 hours ago

$TEVA

ChinaGoingToZero Posted - 13 hours ago

$TEVA RELEASE THE IPO NEWS ALREADY. BANKERS CAN'T KEEP QUIET ABOUT IT 2X INBOUND

infront Posted - 14 hours ago

$TEVA I think now TEVA will hit $20 rather quick !

Phoenixrise1 Posted - 17 hours ago

$TEVA

LakersandVRX Posted - 1 day ago

$TEVA like everyone else here, I hate losing $. Therefore, I ignore the markets until it picks back up again. Pass the time by watching things like the congressional ufo hearings. That last one was crazy. Hope the UFOs don’t take my money. Like I said, I don’t like losing money.

DocDriz Posted - 1 day ago

$TEVA Falling knife after impressive earnings wasn’t going to last forever. Prove to me loading LEAPS down here wasn’t a big mistake TEVA!

infront Posted - 1 day ago

$TEVA A day to remember. TEVA having a green day!

ChinaGoingToZero Posted - 1 day ago

$TEVA RELEASE THE IPO NEWS ALREADY 2X INBOUND

JawadAbuJaber Posted - 2 days ago

$TEVA resistance at 16.50s is huge, but once it break through i think we will start to see the light at the end of the tunnel

swingingtech Posted - 2 days ago

$IEFA $SE $AER $TEVA https://wallstreetwaves.com/significant-capital-inflows-observed-in-iefa-se-aer-and-teva-etfs/

ChinaGoingToZero Posted - 2 days ago

$TEVA IPO NEWS INBOUND

JawadAbuJaber Posted - 2 days ago

$TEVA thoughts on this week?

infront Posted - 4 days ago

$TEVA https://www.bbc.com/news/articles/cp3nzp782ejo

infront Posted - 5 days ago

$TEVA https://m.jpost.com/health-and-wellness/article-829103[

infront Posted - 5 days ago

$TEVA https://www.marketbeat.com/instant-alerts/teva-pharmaceutical-industries-nyseteva-shares-gap-down-should-you-sell-2024-11-15/

NNJAWINLIVE Posted - 5 days ago

$TEVA

infront Posted - 5 days ago

$TEVA ah ha ha SELL THE GARBAGE ha ah ha

DocDriz Posted - 5 days ago

$TEVA Adding today. We go up again next week.

Sdotrayborn Posted - 5 days ago

$TEVA 15.80ish coming 🙏🏻 then I will start to add

infront Posted - 5 days ago

$TEVA Any one think single digits by end of year!

Terrordomo80 Posted - 5 days ago

$TEVA Still plunging from ER. Cause it hasn't dropped enough yet... Oh TEVA... LMAO

LakersandVRX Posted - 5 days ago

$TEVA market seems to be correcting. It was probably a bit overvalued. However, Teva (imo) is not overvalued . The optimist in me says this will not last long but who knows. I still think Teva will fair better in a downturn.

JawadAbuJaber Posted - 6 days ago

$TEVA i dont care, even if it takes couple months, we would get to the 20s. This is a company that was having problems, and now its beating expectations for the 5th quarter,I mean..

Terrordomo80 Posted - 6 days ago

$TEVA here she goes off to new lows closing weak as can be into EOD... Yea...you're fked being long this turd...

TheDudeRooster Posted - 6 days ago

$TEVA Volume dead. 7 red candles in a row on nothing. Definitely waiting out any further add-ons until it shows some life.

Sdotrayborn Posted - 6 days ago

$TEVA patiently waiting ⏰

Sdotrayborn Posted - 6 days ago

$TEVA come on down baby 🙏🏻👍🏻

Notashort45 Posted - 6 days ago

$TEVA Back at 16.70 wow it feels great to be back in at these prices. Going to 32.

ChinaGoingToZero Posted - 6 days ago

$TEVA FILLING THE GAP BEFORE IPO NEWS HITS $37 INBOUND

Terrordomo80 Posted - 6 days ago

$TEVA Teva is dead... Good Night Irene...

Analyst Ratings

UBS	Buy	Sep 3, 24
Barclays	Overweight	Aug 1, 24
UBS	Buy	Jul 10, 24
Jefferies	Buy	Jun 27, 24
Barclays	Overweight	Jun 5, 24
B of A Securities	Buy	May 30, 24
Piper Sandler	Overweight	May 13, 24
Barclays	Overweight	May 9, 24
JP Morgan	Neutral	Mar 8, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Weiss Amir	Chief Accounting Off.. Chief Accounting Officer	Feb 01	Sell	12.3703	31,766	392,955	10,676	02/05/24
Hughes Eric A	See "Remarks" See "Remarks"	Aug 01	Sell	8.3	52,742	437,759		08/03/23
Kalif Eliyahu Sharon	EVP, Chief Financial.. EVP, Chief Financial Officer	Aug 22	Sell	10.0666	55,500	558,696	9,376	08/24/22
Stark David Matthew	Exec. VP Chief Legal.. Exec. VP Chief Legal Officer	Jul 28	Sell	9.0365	58,163	525,590	2,974	07/29/22
Fridriksdottir Hafrun	Executive VP, Global.. Executive VP, Global R&D	May 17	Sell	8.2159	130,000	1,068,067	1,387	05/19/22
Drape Eric	Executive VP Global.. Executive VP Global Operations	Mar 04	Sell	7.44	34,792	258,852	78,072	03/08/22
Dethlefs Sven	EVP, North America C.. EVP, North America Commercial	Mar 04	Sell	7.42	10,897	80,856	165,381	03/08/22
Daniell Richard	Exec. VP, European C.. Exec. VP, European Commercial	Mar 04	Sell	7.44	58,952	438,603	43,182	03/08/22
Stark David Matthew	Exec. VP Chief Legal.. Exec. VP Chief Legal Officer	Feb 28	Sell	8.14	6,452	52,519	21,380	03/02/22
Shani Eli	EVP,Global Marketing.. EVP,Global Marketing&Portfolio	Feb 28	Sell	8.14	5,311	43,232	9,091	03/02/22
Fridriksdottir Hafrun	Executive VP, Global.. Executive VP, Global R&D	Feb 28	Sell	8.14	7,590	61,783	65,509	03/02/22
Drape Eric	Executive VP Global.. Executive VP Global Operations	Feb 28	Sell	8.14	9,797	79,748	45,830	03/02/22
Dethlefs Sven	EVP, North America C.. EVP, North America Commercial	Feb 28	Sell	8.14	4,862	39,577	99,457	03/02/22
Daniell Richard	Exec. VP, European C.. Exec. VP, European Commercial	Feb 28	Sell	8.14	20,598	167,668	20,280	03/02/22
Stark David Matthew	Exec. VP Chief Legal.. Exec. VP Chief Legal Officer	Feb 08	Sell	9.06	6,110	55,357	9,402	02/10/22
Stark David Matthew	Exec. VP Chief Legal.. Exec. VP Chief Legal Officer	May 13	Sell	10.22	37,884	387,174	2,974	05/13/21
Drape Eric	Executive VP Global.. Executive VP Global Operations	May 13	Sell	10.22	19,804	202,397	73,128	05/13/21
Nazzi Gianfranco	EVP, International M.. EVP, International Markets	Mar 08	Sell	10.58	12,935	136,852		03/08/21
Drape Eric	Executive VP Global.. Executive VP Global Operations	Mar 08	Sell	10.58	6,183	65,416	55,048	03/08/21
Dethlefs Sven	EVP Global Marketing.. EVP Global Marketing&Portfolio	Mar 08	Sell	10.57	6,012	63,547	77,976	03/08/21
Nazzi Gianfranco	EVP, International M.. EVP, International Markets	Mar 04	Sell	10.88	1,400	15,232		03/04/21
Fridriksdottir Hafrun	Executive VP, Global.. Executive VP, Global R&D	Feb 17	Sell	11.12	2,098	23,330	103,294	02/17/21
O'Grady Brendan P.	EVP, North America C.. EVP, North America Commercial	Feb 11	Sell	12.69	20,694	262,607	78,146	02/11/21
Dethlefs Sven	EVP Global Marketing.. EVP Global Marketing&Portfolio	Feb 11	Sell	12.69	29,657	376,347	59,404	02/11/21
Daniell Richard	Exec. VP, European C.. Exec. VP, European Commercial	Sep 10	Sell	8.98	333	2,990	10,765	09/10/20